{
  "run_id": "60de0544-01b2-4a11-a3ab-e5612f6c7548",
  "prompt_variant_id": "cec2c1d6-0913-4db7-99bb-7579418dd86f",
  "api_config_name": "model_gpt_3_5_turbo",
  "test_case_id": "breast_cancer_her2_positive",
  "start_time": "2025-09-01T16:32:10.298575",
  "end_time": "2025-09-01T16:32:12.146254",
  "duration_ms": 1845.5970287322998,
  "success": true,
  "error_message": "",
  "entities_extracted": 16,
  "entities_mapped": 14,
  "extraction_completeness": 1.0,
  "mapping_accuracy": 0.45454545454545453,
  "precision": 0.8235294117647058,
  "recall": 0.875,
  "f1_score": 0.8484848484848485,
  "compliance_score": 1.0,
  "token_usage": 3485,
  "extracted_entities": [
    {
      "text": "HER2-Positive Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": null
      },
      "confidence": 0.9,
      "source_context": {
        "section": "Conditions",
        "position": 11,
        "context_sentence": "Conditions: HER2-Positive Breast Cancer, Metastatic Breast Cancer",
        "section_name": "conditionsModule",
        "section_type": "conditions",
        "document_id": "unknown"
      }
    },
    {
      "text": "Metastatic Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": null
      },
      "confidence": 0.9,
      "source_context": {
        "section": "Conditions",
        "position": 39,
        "context_sentence": "Conditions: HER2-Positive Breast Cancer, Metastatic Breast Cancer",
        "section_name": "conditionsModule",
        "section_type": "conditions",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-positive metastatic breast cancer",
      "type": "condition",
      "attributes": {
        "status": "positive"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": 33,
        "context_sentence": "Histologically confirmed HER2-positive metastatic breast cancer",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Measurable disease per RECIST 1.1",
      "type": "condition",
      "attributes": {},
      "confidence": 0.8,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": 64,
        "context_sentence": "Measurable disease per RECIST 1.1",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "ECOG performance status 0-1",
      "type": "demographic",
      "attributes": {},
      "confidence": 0.7,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": 89,
        "context_sentence": "ECOG performance status 0-1",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Adequate organ function",
      "type": "condition",
      "attributes": {},
      "confidence": 0.8,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": 111,
        "context_sentence": "Adequate organ function",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Prior treatment with Trastuzumab Deruxtecan",
      "type": "exclusion",
      "attributes": {},
      "confidence": 0.9,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": 13,
        "context_sentence": "Prior treatment with Trastuzumab Deruxtecan",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Active brain metastases",
      "type": "condition",
      "attributes": {},
      "confidence": 0.8,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": 39,
        "context_sentence": "Active brain metastases",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Pregnancy or breastfeeding",
      "type": "condition",
      "attributes": {},
      "confidence": 0.8,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": 61,
        "context_sentence": "Pregnancy or breastfeeding",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "novel HER2-targeted therapy",
      "type": "medication",
      "attributes": {
        "status": "positive",
        "value": "novel",
        "temporal_context": "current"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "briefSummary",
        "position": 19,
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-positive metastatic breast cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "temporal_context": "current"
      },
      "confidence": 0.8,
      "source_context": {
        "section": "briefSummary",
        "position": 53,
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "progressed on prior trastuzumab-based therapy",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "temporal_context": "past"
      },
      "confidence": 0.7,
      "source_context": {
        "section": "briefSummary",
        "position": 99,
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-Positive Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "temporal_context": "current"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "briefTitle",
        "position": 23,
        "context_sentence": "Study of Novel Therapy in HER2-Positive Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "Phase III Study",
      "type": "procedure",
      "attributes": {},
      "confidence": 0.8,
      "source_context": {
        "section": "officialTitle",
        "position": 2,
        "context_sentence": "A Phase III Study of Novel Targeted Therapy in HER2-Positive Metastatic Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "Novel Targeted Therapy",
      "type": "medication",
      "attributes": {},
      "confidence": 0.85,
      "source_context": {
        "section": "officialTitle",
        "position": 12,
        "context_sentence": "A Phase III Study of Novel Targeted Therapy in HER2-Positive Metastatic Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-Positive Metastatic Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "temporal_context": "current"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "officialTitle",
        "position": 39,
        "context_sentence": "A Phase III Study of Novel Targeted Therapy in HER2-Positive Metastatic Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    }
  ],
  "mcode_mappings": [
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-Positive Breast Cancer",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 0",
      "mapping_rationale": "Mapped to CancerCondition based on the text and confidence level",
      "id": "4d91a2e0-8772-47e6-bd2a-d75c88587b94",
      "llm_source_text_fragment": "Entity index 0",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Metastatic Breast Cancer",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 1",
      "mapping_rationale": "Mapped to CancerCondition based on the text and confidence level",
      "id": "1523f922-74d4-4e45-bc00-7fb48ea25c09",
      "llm_source_text_fragment": "Entity index 1",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-positive metastatic breast cancer",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 2",
      "mapping_rationale": "Mapped to CancerCondition based on the text and confidence level",
      "id": "7711ea9b-3806-4f50-be2c-8ff8f25e8367",
      "llm_source_text_fragment": "Entity index 2",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Measurable disease per RECIST 1.1",
      "mapping_confidence": 0.8,
      "source_text_fragment": "Entity index 3",
      "mapping_rationale": "Mapped to CancerCondition based on the text and confidence level",
      "id": "6847f7cb-4565-4506-afd4-c2296d9667a4",
      "llm_source_text_fragment": "Entity index 3",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "Mcode_element": "ECOGPerformanceStatus",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "ecogperformancestatus",
        "display": "ECOGPerformanceStatus"
      },
      "value": "0-1",
      "mapping_confidence": 0.7,
      "source_text_fragment": "Entity index 4",
      "mapping_rationale": "Mapped to ECOGPerformanceStatus based on the text and confidence level",
      "id": "be2a80e7-72b9-4ea1-bbe6-3ead325b8f78",
      "llm_source_text_fragment": "Entity index 4",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "Mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "Trastuzumab Deruxtecan",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 6",
      "mapping_rationale": "Mapped to CancerRelatedMedication based on the text and confidence level",
      "id": "8f7185b0-1638-4b1c-8c3c-4a071b6a649c",
      "llm_source_text_fragment": "Entity index 6",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Active brain metastases",
      "mapping_confidence": 0.8,
      "source_text_fragment": "Entity index 8",
      "mapping_rationale": "Mapped to CancerCondition based on the text and confidence level",
      "id": "89923a9f-a8b0-4c91-948d-f92ffb991283",
      "llm_source_text_fragment": "Entity index 8",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Pregnancy or breastfeeding",
      "mapping_confidence": 0.8,
      "source_text_fragment": "Entity index 9",
      "mapping_rationale": "Mapped to CancerCondition based on the text and confidence level",
      "id": "8977c10d-1770-425d-8bc5-ffab48745f85",
      "llm_source_text_fragment": "Entity index 9",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "Mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "novel HER2-targeted therapy",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 10",
      "mapping_rationale": "Mapped to CancerRelatedMedication based on the text and confidence level",
      "id": "741a7046-b662-49e4-8460-fc7d7cfaea30",
      "llm_source_text_fragment": "Entity index 10",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-positive metastatic breast cancer",
      "mapping_confidence": 0.8,
      "source_text_fragment": "Entity index 11",
      "mapping_rationale": "Mapped to CancerCondition based on the text and confidence level",
      "id": "0133fa05-6fd5-4271-8ed1-17c18cf17570",
      "llm_source_text_fragment": "Entity index 11",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "progressed on prior trastuzumab-based therapy",
      "mapping_confidence": 0.7,
      "source_text_fragment": "Entity index 12",
      "mapping_rationale": "Mapped to CancerCondition based on the text and confidence level",
      "id": "8fe8ad18-71e8-4aa1-85a1-08bb5efa30cd",
      "llm_source_text_fragment": "Entity index 12",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-Positive Breast Cancer",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 13",
      "mapping_rationale": "Mapped to CancerCondition based on the text and confidence level",
      "id": "6d70a220-fc60-4504-a1d0-4e72106da717",
      "llm_source_text_fragment": "Entity index 13",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "Mcode_element": "GenomicVariant",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "genomicvariant",
        "display": "GenomicVariant"
      },
      "value": "Novel Targeted Therapy",
      "mapping_confidence": 0.85,
      "source_text_fragment": "Entity index 14",
      "mapping_rationale": "Mapped to GenomicVariant based on the text and confidence level",
      "id": "a542a879-273c-425d-84d6-09a91171f596",
      "llm_source_text_fragment": "Entity index 14",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-Positive Metastatic Breast Cancer",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 15",
      "mapping_rationale": "Mapped to CancerCondition based on the text and confidence level",
      "id": "79be60b1-3e87-444b-b074-588e1aa2efbb",
      "llm_source_text_fragment": "Entity index 15",
      "source_references": []
    }
  ],
  "validation_results": {
    "valid": true,
    "errors": [],
    "warnings": [],
    "compliance_score": 1.0
  }
}